Literature DB >> 16764593

Automated red cell collection--quality and value.

J F Harrison1.   

Abstract

Automated red cell collection was initially used largely for therapeutic purposes. New technology has rendered the procedure safer for donors and easier for machine operators. Optimal additive solution can be automatically added and the red cells filtered to provide a leucodepleted product. Two units of red cells may be collected during a single procedure from individuals who have a high enough red cell mass, whilst a single unit of red cells plus platelets or plasma can be collected from smaller donors. In vitro studies suggested that red cells collected by automated methods would be of better quality than those collected by gravity. This was not confirmed in vivo, but red cells collected by automated methods have the major advantage of consistency in terms of haemoglobin content, volume and haematocrit, compared with red cells collected by gravity. This standardised product is of particular value for transfusion dependent patients as the patient's haemoglobin can be maintained within narrow limits. The use of a double dose red cell product for transfusion to a single patient also confers benefit in terms of reduction in donor exposure.

Entities:  

Mesh:

Year:  2006        PMID: 16764593     DOI: 10.1111/j.1365-3148.2006.00651.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  2 in total

1.  Adverse events and retention of donors of double red cell units by apheresis.

Authors:  Ketevan Keshelashvili; Alix O'meara; Martin Stern; Zuzana Jirout; Vildana Pehlic; Andreas Holbro; Andreas Buser; Jörg Sigle; Laura Infanti
Journal:  Blood Transfus       Date:  2016-03-16       Impact factor: 3.443

2.  Long-Term Course of Haemoglobin and Ferritin Values in High-Frequency Donors of Whole Blood and Double Erythrocyte Apheresis.

Authors:  Vildana Pehlic; Thomas Volken; Andreas Holbro; Zuzana Jirout; Beatrice Drexler; Andreas Buser; Laura Infanti
Journal:  Transfus Med Hemother       Date:  2020-08-05       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.